New cancer drug clinical trials struggling

World of DTC Marketing

This translates to longer development times for cancer drugs which means that cancer patients could suffer. It’s essential that drug companies get creative and find new ways to reach patients when incomes to cancer drug screening and clinical trials.

Gilead's Veklury becomes first FDA-approved drug for COVID-19

Bio Pharma Dive

New results from an WHO study, however, raise questions about the drug's ultimate effectiveness The U.S. regulator granted a full approval after allowing emergency use earlier this year.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Launching a drug in a pandemic

World of DTC Marketing

QUICK READ : Prescribers are reviewing some of their favorite prescribed drugs and are open to learning about new drugs in terms of efficacy and patient outcomes but you had better be ready to talk about patients beyond the science.

Drugs 130

Valisure Supports Drug Importation

Pharmacy Checkers

online pharmacy that actually tests the quality of medication it sends to patients and apparently, to my delight, they support drug importation as a policy to lower costs. Food and Drug Administration to make sure those drugs will work as directed by their prescribers.

FDA approves Regeneron antibody drug as first Ebola virus treatment

Bio Pharma Dive

Research for the drug, now cleared as Inmazeb, helped Regeneron jumpstart its fast development of an antibody therapy for COVID-19

Biogen's all-important Alzheimer's drug enters the review gauntlet

Bio Pharma Dive

Meanwhile, the drug has also caught the attention of a powerful cost watchdog group On Nov. 6, aducanumab will go before a panel of experts who will review it and make recommendations to the FDA.

Drugs 261

Pharmacquired: Splashy deals belie a shallow pool of heart drugs left to acquire

Bio Pharma Dive

may be hard to follow, since venture investors and big pharma acquirers have largely ignored cardiovascular drugs Recent deals for MyoKardia and The Medicines Co.

Early signs of survival benefit raise optimism around a small biotech's ALS drug

Bio Pharma Dive

Newly published data show that, after joining a clinical trial, patients who were given a drug from Amylyx Pharmaceutcials lived a median 6.5 months longer than those who didn't

Top 10 myths about working with the FDA for an oncology drug approval

Bio Pharma Dive

Debunking myths around working with the FDA for oncology drug approval

Drugs 232

A new biotech forms to revive Amgen's old heart drug

Bio Pharma Dive

Founders of Dutch biotech Dezima have created NewAmsterdam Pharma and bought back the cholesterol drug they sold to Amgen in 2015

Drugs 197

Lilly, with new data, seeks emergency clearance for COVID-19 antibody drug

Bio Pharma Dive

The pharma is the first to seek emergency approval for this kind of treatment, and may quickly follow up with a second request after reporting promising data for a two-drug combination

Gossamer plummets as its lead drug fails 2 studies

Bio Pharma Dive

Despite the setback, the biotech still sees a path forward for its drug in asthma and plans to find a partner to move it into further testing

Drugs 147

Lilly offers first evidence that its antibody drug may help treat COVID-19

Bio Pharma Dive

The results, from a mid-stage study of Lilly's drug, suggest treatment helped lower virus levels, but the degree to which patients benefited remains unclear

Amgen and Cytokinetics claim heart drug success, but results widely disappoint

Bio Pharma Dive

A weaker-than-expected benefit for omecamtiv mecarbil, a key drug the companies are developing for heart failure, raised doubts about the medicine's potential role

Predicting Cancer Drug Combinations That Work

Pharma R&D Today

He and his colleagues recently published a cancer drug atlas that predicts synergistic combination therapies for cancer. Asked what triggered the idea of a cancer drug atlas, Bart starts with a question he’s asked by cancer clinicians: “I have this patient who is not reacting to therapy.

Drugs 52

Lilly hires consultant to help fix issues at COVID-19 drug manufacturing plant

Bio Pharma Dive

The New Jersey facility that ran afoul of FDA manufacturing standards is one of several Lilly is using to produce coronavirus antibody drugs

Sales targets and bonuses drove Celgene, Teva drug price hikes, lawmakers charge

Bio Pharma Dive

An 18-month investigation by the House Oversight Committee targeted the pricing practices behind the top-selling drugs Revlimid and Copaxone

Sales 183

Sanofi's hemophilia drug comes into focus as delays hit a key competitor

Bio Pharma Dive

With BioMarin's gene therapy sidelined, attention is turning to other drugs, including one Sanofi acquired when it paid $11.6 billion for Bioverativ

Intellia cleared to start key CRISPR drug study in UK

Bio Pharma Dive

The trial would be the first test of a systemically administered gene editing treatment that uses the Nobel Prize-winning technology to alter DNA

How DNA-encoded Libraries Boost Drug Discovery

Pharma R&D Today

DNA-encoded libraries (DELs) have been gaining a lot of traction in hit finding and drug discovery in recent years. Vertex Pharmaceuticals has paired up with X-Chem in order to utilize their DELs for drug discovery.

DNA 52

Drug repurposing

Scienmag

University of New Mexico researchers find existing medications may fight coronavirus infection University of New Mexico researchers who combed through a “library” of previously approved drugs believe they have identified a medication with the potential to help speed a patient’s recovery from SARS-CoV-2 infection. “The gist of it is we think we found a drug […].

Regeneron enlists Roche to boost production of COVID-19 antibody drug

Bio Pharma Dive

Together, the companies expect to make three and a half times as many doses of Regeneron's antibody drug than the U.S. biotech could on its own

Half a million-dollar bonus for cancer drug price increase

World of DTC Marketing

Pharma CEO’s serve themselves with big salaries tied to drug prices and keeping drugs from coming off patent. On Wednesday, three pharmaceutical executives, including former Celgene CEO Mark Alles, testified on drug pricing for the House Oversight Committee.

House committee to subpoena AbbVie over drug pricing

Bio Pharma Dive

Democratic lawmakers have been unhappy with AbbVie's response to an ongoing drug pricing probe, and are now demanding the drugmaker turn over more information

Drugs 154

Rep. Schakowsky (D-IL) Gets an A+ on Drug Prices in Congressional Report Card

Pharmacy Checkers

The highest score in the Prescription Justice Congressional Report Card on Drug Prices – 100 – goes to Representative Jan Schakowsky (D-IL) , with a grade of A+. If all members of Congress hopped on the drug price lowering bandwagon just like Rep. Drug Prices

Drugs 52

AbbVie wagers up to $2B on a Chinese biotech's cancer drug

Bio Pharma Dive

The licensing deal hands AbbVie exclusive rights to a drug that targets CD47, a protein which has caught the attention of other large drugmakers like Gilead and Celgene

Gilead's COVID-19 drug doesn't prevent deaths, large WHO study finds

Bio Pharma Dive

The results could weaken the case for widely using Veklury, also known as remdesivir, just as the company is asking for full approval from the FDA

Drugs 211

Mirati cancer drug results spark hopes of outperforming Amgen's

Bio Pharma Dive

The biotech's KRAS-blocking pill trails Amgen's sotorasib in development, but early data suggest it might match the bar set by Amgen

Blueprint's bet on itself pays off with rare disease drug data

Bio Pharma Dive

Study data show Blueprint's first approved cancer drug, Ayvakit, could also work to treat a rare disease, a result that sent the company's shares higher

Drugs 203

Sanofi ends research of arthritis drug as coronavirus treatment

Bio Pharma Dive

Kevzara failed to shorten hospital stays among patients severely sick with COVID-19, study results showed, further dimming hopes that drugs similar to it could help combat the disease

A hedge fund bets on a biotech startup to bring new drugs to China

Bio Pharma Dive

The unusual startup already has partial rights to multiple drugs developed by MyoKardia and affiliates of BridgeBio, and plans to acquire many more

Blueprint's cancer drug approval puts it up against Lilly

Bio Pharma Dive

Partners Blueprint and Roche will now compete with Eli Lilly and its rival drug Retevmo Gavreto is cleared to treat certain lung cancer patients who have so-called RET mutations.

Drugs 150

FDA agrees to review Biogen's Alzheimer's drug

Bio Pharma Dive

The agency's decision kicks off a historic and dramatic regulatory review, as significant lingering questions surround aducanumab's approval chances

Drugs 193

New drug carrier systems

Scienmag

University of Delaware researchers advance drug delivery systems to treat connective tissue disorders Credit: Graphic illustration by Jeffrey C.

Merck pays Seattle Genetics $1.7B as antibody cancer drugs continue comeback

Bio Pharma Dive

Merck's deal for Seattle Genetics' antibody-drug conjugate comes as Gilead agreed to acquire rival developer Immunomedics in the biotech industry's largest buyout of 2020

Congress, Not Pharma Execs, Are Accountable to Voters on Drug Prices

Pharmacy Checkers

There’s a lot of talk on PharmacyCheckerBlog about Big Pharma doing this and Big Pharma doing that to keep drug prices high in America. This week, we at Prescription Justice announced the new Congressional Report Card on Drug Prices. Drug PricesCongress is on my mind this week.

Merck details cough drug data, raising questions about its potential

Bio Pharma Dive

Merck's drug could be the first-ever treatment for chronic cough, a condition that afflicts millions. But side effects and modest efficacy may limit its use

Drugs 134

First oral drug for spinal muscular atrophy approved by FDA

Bio Pharma Dive

Approval of Evrysdi, from Roche and PTC Therapeutics, adds a third option for treating the neuromuscular disease, joining Spinraza and Zolgensma

Drugs 274

Explaining Rep. Pelosi’s F Grade on Drug Prices

Pharmacy Checkers

Prescription Justice has graded all members of Congress in a drug prices report card. 3, the Elijah Cummings Lower Drug Costs Now Act, through the House and vociferously called for its passage on the House floor, as read on the Speaker’s website. Drug Prices

HR 57

FDA opens door to expressly permit personal drug importation, and yet…

Pharmacy Checkers

In most cases, the reason is that the same drugs sold in the U.S. million Americans import drugs to save money each year. First, wholesale importation of lower cost drugs from Canada is now lawful. That is pursuant to Section 804 of the Food, Drug and Cosmetic Act.